Agios leases Cambridge space for cancer lab

Agios Pharmaceuticals said today it has leased a 21,000 square-foot facility in Cambridge to create a laboratory dedicated to cancer metabolism research.

"At Agios we are committed to building a transformative product company with a bold vision driven by great science with the best people. As part of this commitment, we believe our investment in a new fully equipped facility with biology, chemistry, and deep platform capabilities is a critical part of our ability to explore this novel area of cancer therapeutics," Kevin Starr, interim chief executive, said in a statement.

Starr is also a partner at Third Rock Ventures LLC, a Boston investment firm focused on the life sciences industry.

To read a July story in the Globe about Agios raising $33 million in venture capital, please click here.
(By Chris Reidy, Globe staff)